A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail PF

Femoral Fracture Clinical Trial

Official title:

A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail Piriformis Fossa (PF) of the T2 Alpha Femur Antegrade GT/PF Nailing System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04015154
• Other study ID #: T2 Alpha Femur Antegrade PF
• Status: Recruiting
• Start date: September 12, 2019
• Est. completion date: June 2025

Study information

• Verified date: June 2024
• Source: Stryker Trauma and Extremities
• Contact: Monica Fleeman
• Phone: 251 465 5969
• Email: monica.fleeman[@]stryker.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This investigation is a prospective, multicenter clinical investigation. It is anticipated that a total of 50 subjects will be enrolled at up to 5 sites. Enrollment is estimated to commence in Q4 of 2018. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System.

Total duration of enrollment, 12 month follow-up and analysis is expected to take 29 months. The clinical investigation has been designed to follow the surgeon's standard of care for femur fractured subjects, in addition to a 12 month follow-up visit.

The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the Lower Extremity Measure (LEM). Confirmation of efficacy/performance at 12 months will be based on an equal or greater (non-inferior) LEM score result of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System compared to the T2 Femur benchmark literature.

Description:

The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System. Efficacy/performance of the procedure will be measured by an equal or greater (non-inferior) Lower Extremity Measure (LEM) score result of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System compared to the T2 Femur benchmark literature at 12 months.

In addition, demonstration of bone consolidation in correct alignment will be measured by Investigator assessment by 12 months. Safety of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System will be demonstrated through reporting of device related intra-operative and post-operative Adverse Events/incidents by 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is a male or non-pregnant female age 18 years or older at the time of surgery;

• Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan;

• Subject is intended to be treated with the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System in accordance with the following legally cleared/ approved Indications for Use:

Indications for Use:

• Fixation of subtrochanteric, intertrochanteric, ipsilateral neck/shaft, comminuted proximal femoral shaft fractures

• Femoral fixation required as a result of pathological disease

• Temporary stabilization of fractures of the femoral shaft ranging from the femoral neck to the supracondylar regions of the femur

• Open and closed femoral fractures

• Pseudoarthrosis and correction osteotomy

• Pathologic fractures, impending pathologic fractures and tumor resections

• Ipsilateral femur fractures

• Fractures proximal to a total knee arthroplasty

• Nonunions and malunions

• Fractures involving osteopenic and osteoporotic bone

Exclusion Criteria:

• Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;

• Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).

Related Conditions & MeSH terms

• Femoral Fracture
• Femoral Fractures
• Fractures, Bone

Intervention

Device:
• Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System
The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.

Locations

Country	Name	City	State
United States	UC Health	Cincinnati	Ohio
United States	Inova Fairfax Medical Campus	Falls Church	Virginia
United States	Ariana Meltzer-Bruhn	New York	New York
United States	Reno Orthopedic Clinic	Reno	Nevada
United States	St. Cloud Orthopedic Associates, Ltd	Sartell	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Stryker Trauma and Extremities

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lower Extremity Measure (LEM)	The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the Lower Extremity Measure (LEM). Confirmation of efficacy/performance at 12 months will be based on an equal or greater (non-inferior) LEM score result of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System compared to the T2 Femur benchmark literature	12 months
Secondary	Safety will be measured by capturing the incidence rate of device-related adverse events	Incidence of device-related adverse events will be monitored by 12 months through data collection and analyses.	12 months
Secondary	Efficacy/Performance will be measured by demonstration of bone consolidation	Bone consolidation will be assessed by 12 months as measured by Investigator assessment.	12 months